{"id":28538,"date":"2024-11-10T00:47:45","date_gmt":"2024-11-10T00:47:45","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=28538"},"modified":"2024-11-10T00:47:45","modified_gmt":"2024-11-10T00:47:45","slug":"gsk-ve-cambridge-universitesi-bobrek-ve-solunum-hastaliklarinda-bes-yillik-yeni-bir-is-birligi-duyurdu","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/gsk-ve-cambridge-universitesi-bobrek-ve-solunum-hastaliklarinda-bes-yillik-yeni-bir-is-birligi-duyurdu\/","title":{"rendered":"GSK ve Cambridge \u00dcniversitesi, b\u00f6brek ve solunum hastal\u0131klar\u0131nda be\u015f y\u0131ll\u0131k yeni bir i\u015f birli\u011fi duyurdu"},"content":{"rendered":"

GSK, Cambridge \u00dcniversitesi ve Cambridge \u00dcniversitesi Hastaneleri ile ba\u011f\u0131\u015f\u0131kl\u0131k sistemiyle ilgili hastal\u0131klar \u00fczerine ara\u015ft\u0131rma ve geli\u015ftirmeyi h\u0131zland\u0131rmak amac\u0131yla 50 milyon sterlinlik b\u00fcy\u00fck bir yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131 duyurdu. Cambridge-GSK Translasyonel \u0130mm\u00fcnoloji \u0130\u015f Birli\u011fi (CG-TIC) olarak adland\u0131r\u0131lan bu yeni i\u015f birli\u011fi, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi kaynakl\u0131 hastal\u0131klar\u0131n tedavisinde daha hassas ve h\u0131zl\u0131 \u00e7\u00f6z\u00fcmler geli\u015ftirmeyi hedefliyor. \u00d6zellikle yapay zek\u00e2 ve makine \u00f6\u011frenimi kullan\u0131larak, b\u00f6brek ve solunum hastal\u0131klar\u0131n\u0131n tedavisinde yeni y\u00f6ntemler bulunmas\u0131 ama\u00e7lan\u0131yor.<\/p>\n

\u0130ki ana hastal\u0131k alan\u0131na odaklan\u0131lacak: B\u00f6brek ve Solunum Hastal\u0131klar\u0131<\/strong><\/h4>\n

Yap\u0131lan ara\u015ft\u0131rmalara g\u00f6re d\u00fcnya genelinde 850 milyon ki\u015fi b\u00f6brek hastal\u0131\u011f\u0131ndan ve 545 milyon ki\u015fi kronik solunum yolu hastal\u0131klar\u0131ndan muzdarip.[1]<\/a>–[2]<\/a><\/sup> GSK, bu i\u015f birli\u011fiyle b\u00f6brek ve solunum hastal\u0131klar\u0131 alan\u0131na odaklanarak, hastal\u0131klar\u0131n mevcut tedavi yollar\u0131n\u0131 iyile\u015ftirmek ve geli\u015ftirmek i\u00e7in Cambridge \u00dcniversitesi\u2019nin g\u00fc\u00e7l\u00fc teknoloji altyap\u0131s\u0131 ile kendi Ar-Ge g\u00fcc\u00fcn\u00fc birle\u015ftiriyor.<\/p>\n

GSK Bilimsel Ara\u015ft\u0131rmalar Direkt\u00f6r\u00fc Tony Wood<\/strong>, \u201cBilimsel ilerlemenin merkezinde i\u015f birli\u011fi yer al\u0131r ve bu, GSK’da nas\u0131l Ar-Ge \u00e7al\u0131\u015fmalar\u0131 y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz\u00fcn temelini olu\u015fturur. Cambridge \u00dcniversitesi ile mevcut \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131 geni\u015fleterek, Birle\u015fik Krall\u0131k\u2019taki bu d\u00fcnya lideri bilimsel ve teknolojik kapasiteyi daha da geli\u015ftirece\u011fimiz i\u00e7in heyecanl\u0131y\u0131z. Cambridge\u2019in uzmanl\u0131\u011f\u0131 ve GSK\u2019n\u0131n ila\u00e7 geli\u015ftirme s\u00fcrecini h\u0131zland\u0131racak ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ve yapay zek\u00e2 alan\u0131ndaki bilimsel birikimi ile tedavisi zor hastal\u0131klarla m\u00fccadele eden hastalara yard\u0131mc\u0131 olma f\u0131rsat\u0131na sahibiz\u201d dedi.<\/p>

\"\"<\/a><\/div>\n

Cambridge \u00dcniversitesi Rekt\u00f6r\u00fc Profes\u00f6r Deborah Prentice ve Birle\u015fik Krall\u0131k Bilim, \u0130novasyon ve Teknoloji Bakan\u0131 Peter Kyle<\/strong>, bu i\u015f birli\u011finin \u00f6nemine dikkat \u00e7ekerek, yapay zek\u00e2 kullanarak ba\u011f\u0131\u015f\u0131kl\u0131k sistemiyle ilgili hastal\u0131klar\u0131n tedavisini ilerletme ve d\u00fcnya \u00e7ap\u0131nda hastalara \u00f6nemli faydalar sa\u011flama potansiyeline sahip oldu\u011funu belirtti.<\/p>\n

Cambridge-GSK Translasyonel \u0130mm\u00fcnoloji \u0130\u015f Birli\u011fi (CG-TIC), GSK Klinik Ara\u015ft\u0131rmalar Ba\u015fkan\u0131 Nicolas Wisniacki ve Cambridge Terap\u00f6tik \u0130mm\u00fcnoloji ve Bula\u015f\u0131c\u0131 Hastal\u0131klar Enstit\u00fcs\u00fc\u2019nde b\u00f6brek hastal\u0131klar\u0131 ba\u015f ara\u015ft\u0131rmac\u0131s\u0131 Prof. David Thomas taraf\u0131ndan y\u00f6netilecek.<\/p>\n

[1]<\/a> https:\/\/www.theisn.org\/more-than-850-million-worldwide-have-some-form-of-kidney-disease-help-raise-awareness\/<\/p>\n

[2]<\/a> https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(20)30157-0\/fulltext<\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

GSK, Cambridge \u00dcniversitesi ve Cambridge \u00dcniversitesi Hastaneleri ile ba\u011f\u0131\u015f\u0131kl\u0131k sistemiyle ilgili hastal\u0131klar \u00fczerine ara\u015ft\u0131rma ve geli\u015ftirmeyi h\u0131zland\u0131rmak amac\u0131yla 50 milyon sterlinlik b\u00fcy\u00fck bir yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131 duyurdu. Cambridge-GSK Translasyonel \u0130mm\u00fcnoloji \u0130\u015f Birli\u011fi (CG-TIC) olarak adland\u0131r\u0131lan bu yeni i\u015f birli\u011fi, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi kaynakl\u0131 hastal\u0131klar\u0131n tedavisinde daha hassas ve h\u0131zl\u0131 \u00e7\u00f6z\u00fcmler geli\u015ftirmeyi hedefliyor. \u00d6zellikle yapay zek\u00e2 ve makine \u00f6\u011frenimi kullan\u0131larak, b\u00f6brek ve solunum hastal\u0131klar\u0131n\u0131n tedavisinde yeni y\u00f6ntemler bulunmas\u0131 ama\u00e7lan\u0131yor. \u0130ki ana hastal\u0131k alan\u0131na odaklan\u0131lacak: B\u00f6brek ve Solunum Hastal\u0131klar\u0131 Yap\u0131lan ara\u015ft\u0131rmalara g\u00f6re d\u00fcnya genelinde 850 milyon ki\u015fi b\u00f6brek hastal\u0131\u011f\u0131ndan ve 545 milyon ki\u015fi kronik solunum yolu hastal\u0131klar\u0131ndan muzdarip.[1]–[2] GSK, bu i\u015f birli\u011fiyle b\u00f6brek ve […]<\/p>\n","protected":false},"author":1,"featured_media":28539,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-28538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genel"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/28538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=28538"}],"version-history":[{"count":0,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/28538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/28539"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=28538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=28538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=28538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}